Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Harrow, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
HROW
Nasdaq
2830
www.harrow.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Harrow, Inc.
Harrow Partners with Cencora to Launch "Harrow Cares" Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
- Jan 27th, 2025 12:30 pm
3 US Growth Companies With High Insider Ownership Seeing Up To 39% Revenue Growth
- Jan 22nd, 2025 3:05 pm
Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
- Jan 7th, 2025 12:00 pm
3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth
- Dec 24th, 2024 3:01 pm
US Growth Stocks With High Insider Ownership To Watch
- Nov 25th, 2024 11:01 am
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
- Nov 21st, 2024 12:00 pm
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
- Nov 20th, 2024 12:00 pm
Harrow Announces Participation in Upcoming Investor Conferences
- Nov 15th, 2024 12:00 pm
Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...
- Nov 15th, 2024 7:06 am
Harrow Announces Third Quarter 2024 Financial Results
- Nov 13th, 2024 9:34 pm
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
- Nov 13th, 2024 12:00 pm
Harrow Announces Market Access Wins for VEVYE®
- Nov 12th, 2024 12:00 pm
Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
- Nov 7th, 2024 12:00 pm
Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
- Oct 31st, 2024 11:00 am
3 US Growth Stocks With High Insider Ownership And 167% Earnings Growth
- Oct 18th, 2024 11:00 am
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
- Oct 10th, 2024 11:00 am
Harrow Relaunches TRIESENCE®
- Oct 3rd, 2024 11:00 am
Harrow, Inc. (HROW): A Bull Case Theory
- Oct 2nd, 2024 3:10 pm
Harrow Announces Nashville Expansion
- Sep 25th, 2024 4:02 pm
Three US Growth Companies With High Insider Ownership
- Sep 19th, 2024 11:06 am
Scroll